Erythromycin base tablets

Claim 2

An enteric coated erythromycin base tablet consisting essentially of a tablet core and a tablet coating, said core consisting essentially of 250 parts of erythromycin base in the form of its dihydrate, 35 to 100 parts of a highly water soluble orally nontoxic ingestible salt, and 40 to 165 parts of lubricants, binders, diluents and disintegrants, and said core being coated from a solution consisting essentially of 16 to 25 parts of hydroxypropyl methylcellulose phthalate in an ethanol/water mixture containing pigments, plasticizers, dyes and flavoring agents, said core forming an integral and impervious envelope over said core, and, if desired, a further, outer and clear coating applied from a solution containing said hydroxypropyl methylcellulose phthalate, plasticizer and flavoring components in an ethanol/water mixture.

Claim 3

The tablet of claim 1 wherein said ingestible nontoxic salt is sodium citrate.

Claim 4

The tablet of claim 1 wherein said orally nontoxic salt is potassium chloride.

Claim 5

A tablet according to claim 1 wherein said water soluble nontoxic salt is present in an amount of 40-65 parts and said lubricants, binders, diluents and disintegrants are present in an amount of 65-105 parts.

Claim 6

The tablet of claim 4 wherein said water soluble nontoxic salt is sodium citrate.

Claim 7

The tablet of claim 4 wherein said water soluble nontoxic salt is potassium chloride.

Claim 8

The process of making an erythromycin base tablet core comprising the steps of (a) preparing a tablet core consisting essentially of 100 parts of erythromycin base dihydrate, 8-32 parts of a highly water soluble, orally nontoxic salt, 1-5 parts of a pharmaceutically acceptable binder, 8-32 parts of a pharmaceutically acceptable disintegrant, and 2-9 parts of tableting glidants and lubricants, (b) compressing said component in the usual fashion into the shape of a pharmaceutical tablet, and (c) coating said tablet from a mixture containing 6.4-10 parts of hydroxypropyl methylcellulose phthalate, 0.6-1.0 parts of one or more plasticizers, 0.04-0.06 parts of a water soluble dye or dye mixture, 0.6-0.9 parts titanium dioxide in 80-125 parts of a 75-85% aqueous ethanol, and if desired, (d) applying a clear outer coating to said coated tablet from a coating mixture containing 6.4-10 parts of hydroxypropyl methylcellulose phthalate, 0.6-1.0 of a plasticizer and optional flavoring agents in a 75-80% aqueous ethanol vehicle.

Claim 9

The process of making an erythromycin base tablet core comprising the steps of (a) preparing a tablet core consisting essentially of 100 parts of erythromycin base dihydrate, 8-32 parts of a highly water soluble, orally nontoxic salt, 1-5 parts of a pharmaceutically acceptable binder, 8-32 parts of a pharmaceutically acceptable disintegrant, and 2-9 parts of tableting glidants and lubricants, (b) compressing said component in the usual fashion into the shape of a pharmaceutical tablet, and (c) coating said tablet from a mixture containing 6.4-10 parts of hydroxypropyl methylcellulose phthalate, 0.6-1.0 parts of one or more plasticizers, 0.04-0.06 parts of a water soluble dye or dye mixture, 0.6-0.9 parts titanium dioxide in 80-125 parts of a 75-85% aqueous ethanol, and if desired, (d) applying a clear outer coating to said coated tablet from a coating mixture containing 6.4-10 parts of hydroxypropyl methylcellulose phthalate, 0.6-1.0 of a plasticizer and optional flavoring agents in a 75-80% aqueous ethanol vehicle.

Claim 10

The process of claim 7 wherein said non-toxic salt is sodium citrate.

Claim 11

The process of claim 7 wherein said non-toxic salt is potassium chloride.